1. Home
  2. RLMD vs CNVS Comparison

RLMD vs CNVS Comparison

Compare RLMD & CNVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLMD
  • CNVS
  • Stock Information
  • Founded
  • RLMD 2004
  • CNVS 2000
  • Country
  • RLMD United States
  • CNVS United States
  • Employees
  • RLMD N/A
  • CNVS N/A
  • Industry
  • RLMD Biotechnology: Pharmaceutical Preparations
  • CNVS Consumer Electronics/Video Chains
  • Sector
  • RLMD Health Care
  • CNVS Consumer Discretionary
  • Exchange
  • RLMD Nasdaq
  • CNVS Nasdaq
  • Market Cap
  • RLMD 67.7M
  • CNVS 64.1M
  • IPO Year
  • RLMD N/A
  • CNVS 2003
  • Fundamental
  • Price
  • RLMD $2.09
  • CNVS $3.19
  • Analyst Decision
  • RLMD Hold
  • CNVS Buy
  • Analyst Count
  • RLMD 2
  • CNVS 2
  • Target Price
  • RLMD $1.00
  • CNVS $9.50
  • AVG Volume (30 Days)
  • RLMD 335.3K
  • CNVS 105.7K
  • Earning Date
  • RLMD 11-07-2025
  • CNVS 11-13-2025
  • Dividend Yield
  • RLMD N/A
  • CNVS N/A
  • EPS Growth
  • RLMD N/A
  • CNVS N/A
  • EPS
  • RLMD N/A
  • CNVS 0.13
  • Revenue
  • RLMD N/A
  • CNVS $80,173,000.00
  • Revenue This Year
  • RLMD N/A
  • CNVS $0.76
  • Revenue Next Year
  • RLMD N/A
  • CNVS N/A
  • P/E Ratio
  • RLMD N/A
  • CNVS $23.92
  • Revenue Growth
  • RLMD N/A
  • CNVS 77.07
  • 52 Week Low
  • RLMD $0.24
  • CNVS $2.13
  • 52 Week High
  • RLMD $3.98
  • CNVS $7.39
  • Technical
  • Relative Strength Index (RSI)
  • RLMD 55.74
  • CNVS 36.63
  • Support Level
  • RLMD $1.98
  • CNVS $3.09
  • Resistance Level
  • RLMD $2.27
  • CNVS $3.31
  • Average True Range (ATR)
  • RLMD 0.21
  • CNVS 0.16
  • MACD
  • RLMD -0.04
  • CNVS 0.04
  • Stochastic Oscillator
  • RLMD 64.22
  • CNVS 21.74

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

About CNVS Cineverse Corp.

Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.

Share on Social Networks: